Secondary Hypogonadism: Stopping Treatment Safely

What Makes Secondary Hypogonadism Different at Discontinuation

Secondary hypogonadism means the testes themselves are not the problem. The pituitary gland fails to secrete enough LH and FSH, so the testes receive no signal to produce testosterone or sperm. Because testicular Leydig and Sertoli cells remain intact, restoring the upstream signal can restore function, a possibility that does not exist in primary hypogonadism.

The 2018 Endocrine Society Clinical Practice Guideline on male hypogonadism states directly: "We suggest offering testosterone therapy to men with classical hypogonadism, but clinicians should first consider whether the cause is potentially reversible." (Bhasin S et al., JCEM 2018) That single sentence carries significant clinical weight at discontinuation: reversible causes must be re-evaluated before any taper begins.

The HPG Axis and Why It Matters for Stopping

The hypothalamic-pituitary-gonadal (HPG) axis operates on negative feedback. Exogenous testosterone suppresses GnRH pulses within 24-48 hours and LH/FSH secretion within days. A 2006 study in JCEM (N=72) showed complete gonadotropin suppression in men receiving 200 mg testosterone enanthate weekly by week 2. After stopping, the axis must rebuild pulse amplitude from near zero, a process measured in months, not days.

Reversible Causes That Change the Stopping Plan

Before any discontinuation protocol, screen for:

• Hyperprolactinemia: Prolactin above 20 ng/mL suppresses GnRH. Dopamine agonist therapy (cabergoline 0.5 mg twice weekly) often restores axis function without ever needing testosterone. A Cochrane review confirmed cabergoline as first-line for prolactinoma-related hypogonadism.
• Opioid-induced androgen deficiency (OPIAD): Chronic opioid use suppresses LH in roughly 74% of men. (Daniell HW, Pain Physician 2006) Dose reduction or rotation may restore axis function.
• Obesity-related hypogonadism: BMI >35 is independently associated with suppressed LH. Weight loss of 10-15% has been shown to raise total testosterone by 2.9 nmol/L in men with obesity-associated hypogonadism. (Grossmann M, Eur J Endocrinol 2018)
• Hemochromatosis: Iron deposition in the pituitary suppresses gonadotropin secretion; phlebotomy can reverse this.
• Glucocorticoid excess: Both exogenous and endogenous Cushing's suppress GnRH pulsatility.

Identifying and treating the reversible cause first may render a full discontinuation protocol unnecessary.

Stopping Exogenous Testosterone in Secondary Hypogonadism

Why Cold Turkey Is Rarely the Right Approach

Abrupt testosterone cessation leaves patients symptomatic for weeks to months while the HPG axis recovers. Total testosterone can drop below 200 ng/dL within 2-3 weeks of stopping weekly injections, causing fatigue, low libido, depression, and cognitive fog. The goal of a structured stopping plan is to minimize this symptomatic trough.

The Standard Three-Phase Discontinuation Protocol

Phase 1 (weeks 1-4): Extend the injection interval or reduce dose

For patients on testosterone cypionate or enanthate, extend the injection interval from 7 days to 10-14 days, or reduce the weekly dose by 50%. For topical gels, reduce to half the daily dose. This prevents a sharp drop while the HPG axis begins to wake up.

Phase 2 (weeks 4-12): Bridge with a SERM or hCG

Clomiphene citrate 25-50 mg daily or enclomiphene 12.5-25 mg daily can be started as testosterone is lowered. These agents block estrogen receptors at the hypothalamus and pituitary, disinhibiting GnRH and gonadotropin secretion. A randomized trial by Kim et al. (JCEM 2013, N=36) showed clomiphene raised total testosterone from 237 to 610 ng/dL over 3 months while preserving spermatogenesis. Enclomiphene, the trans-isomer, carries less estrogenic activity and has shown equivalent LH and testosterone stimulation with fewer side effects in Phase 3 data. (Wiehle R et al., BJU Int 2013)

Alternatively, hCG 1,500-3,000 IU three times per week directly stimulates LH receptors on Leydig cells and maintains intratesticular testosterone during the transition. Coviello et al. (JCEM 2004) demonstrated that hCG 125 IU every other day maintains intratesticular testosterone at near-normal levels during testosterone suppression.

Phase 3 (months 3-6): Wean the bridge agent

Once morning total testosterone on two measurements exceeds 400 ng/dL and LH is detectable (above 2 mIU/mL), the SERM or hCG dose can be reduced by 50% every 4 weeks. Some patients with an identified and corrected reversible cause stop needing any medication at this point.

Lab Monitoring Timeline After Stopping Testosterone

| Timepoint | Labs to Check | |---|---| | 6-8 weeks post-stop | Total T, free T, LH, FSH, SHBG, prolactin | | 3 months | Total T, LH, FSH, hematocrit (normalize after stopping) | | 6 months | Full panel including metabolic and PSA if applicable | | 12 months | Repeat full panel; consider DXA if T remains <300 ng/dL |

Hematocrit typically normalizes within 3-6 months of stopping testosterone. The FDA prescribing information for testosterone products lists polycythemia as a dose-dependent adverse effect requiring dose reduction or cessation.

Stopping Enclomiphene or Clomiphene Therapy

Enclomiphene and clomiphene are often the primary treatment for secondary hypogonadism, particularly in younger men or those with fertility goals. Stopping them is generally more straightforward than stopping testosterone, but requires a plan.

How SERM Therapy Affects the Axis

SERMs do not suppress the HPG axis. They maintain or stimulate LH and FSH secretion throughout treatment. This means that after stopping a SERM, the axis does not need to "restart" from suppression. The concern is whether endogenous testosterone will remain adequate once the SERM-driven LH stimulation is removed.

When Testosterone Holds After Stopping a SERM

If the underlying cause of low gonadotropins has been corrected (weight loss, prolactin normalized, opioid dose reduced), testosterone may remain above 400 ng/dL after stopping the SERM. Check LH, FSH, and total testosterone 6-8 weeks after the last dose. The Endocrine Society guideline notes that clomiphene-treated patients with idiopathic hypogonadotropic hypogonadism have a 10-20% chance of sustained reversal.

When Testosterone Falls After Stopping a SERM

A drop below 300 ng/dL with symptoms 6-8 weeks after stopping indicates the underlying hypogonadism is not resolved. Options at this point: resume SERM at the lowest effective dose, transition to hCG if fertility is the goal, or accept ongoing SERM use as long-term management.

Long-term clomiphene use beyond 12 months carries some theoretical concern for retinal toxicity (based on case reports in women), though prospective data in men are limited. Enclomiphene lacks this concern based on current evidence. (Krzastek SC et al., Urology 2019)

Stopping hCG Therapy

hCG Monotherapy Discontinuation

HCG mimics LH at the testicular receptor. Stopping it does not require a taper in most cases because it does not suppress endogenous gonadotropin secretion. After the last injection (half-life approximately 36 hours), LH and FSH from the pituitary can resume driving testicular function within days.

Check LH, FSH, and total testosterone 4-6 weeks after the last hCG dose. If LH rises but testosterone remains low, consider primary testicular dysfunction co-existing with the central cause. Liu PY et al. (NEJM 2006, N=283) showed that men with hypogonadotropic hypogonadism treated with pulsatile GnRH or gonadotropins had sperm production restored in 80% of cases, confirming that the testes themselves are functional in this population.

hCG Plus FSH Combination: Post-Treatment Expectations

Men treated with combined hCG and recombinant FSH (rFSH) for spermatogenesis induction should expect spermatogenesis to decline within 2-3 months of stopping rFSH. A washout of 3-6 months is needed before accurate sperm count assessment. A meta-analysis by Rohayem et al. (Andrology 2015) found median time to sperm appearance with combined gonadotropin therapy was 7.7 months in congenital hypogonadotropic hypogonadism.

Fertility Goals Change the Entire Discontinuation Plan

Never Stop to Try for a Pregnancy Without a Transition Plan

Stopping testosterone cold to achieve fertility is one of the most common clinical errors in secondary hypogonadism management. After exogenous testosterone suppresses gonadotropins, spermatogenesis takes 3-6 months to recover fully, and in men who used testosterone for more than 2 years, recovery to a sperm concentration above 20 million/mL may take 12-24 months (Gu et al., WHO Male Methods Study follow-up data).

The Recommended Fertility Transition Protocol

When a patient on testosterone therapy wishes to conceive:

1. Stop testosterone completely. Do not taper.
2. Start hCG 1,500-3,000 IU three times per week immediately.
3. Add rFSH 75-150 IU three times per week if no spermatogenesis after 6 months on hCG alone.
4. Check semen analysis at 6 months and every 3 months thereafter.
5. Do not restart testosterone until fertility goals are completed.

The Endocrine Society guideline explicitly recommends gonadotropin therapy (hCG ± FSH) over testosterone for men with hypogonadotropic hypogonadism who desire fertility.

Special Populations: Stopping Treatment in Complex Cases

Men With a Pituitary Adenoma

Patients whose secondary hypogonadism was caused by a pituitary macroadenoma require neuroimaging follow-up when treatment is changed. If surgical or radiation treatment has addressed the adenoma, the HPG axis may recover. Stopping testosterone in this group requires baseline pituitary MRI within 3 months and close monitoring of LH/FSH to distinguish true axis recovery from persistent pituitary insufficiency.

Panhypopituitarism after pituitary surgery means testosterone therapy may be lifelong. Do not stop testosterone in a post-surgical patient without endocrine specialist guidance.

Men With Kallmann Syndrome or Congenital HH

Congenital hypogonadotropic hypogonadism (CHH), including Kallmann syndrome, is defined by absent or severely reduced GnRH secretion from birth. Spontaneous HPG axis recovery after stopping treatment occurs in a minority, approximately 10-20% based on natural history data. (Raivio T et al., NEJM 2007, N=31) These patients generally require lifelong treatment, though a 3-6 month trial off therapy under laboratory monitoring is reasonable when the patient requests it.

Adolescents and Young Men on Treatment

Boys started on testosterone for delayed puberty may be able to stop treatment once endogenous puberty initiates. Checking LH, FSH, and testosterone 3-4 months after stopping is standard. Palmert MR and Dunkel L (NEJM 2012) provided the clinical framework for distinguishing constitutional delay of puberty from CHH, with the key differentiator being LH pulse response to GnRH stimulation.

Managing Symptoms During the Transition Off Treatment

Short-Term Symptom Control Without Restarting Testosterone

Fatigue and low mood during HPG axis recovery are common. Non-hormonal options:

• Sleep hygiene optimization: Testosterone is secreted preferentially during sleep. Fixing sleep apnea (present in up to 70% of hypogonadal men with obesity) can raise testosterone by 200-300 ng/dL. (Luboshitzky R et al., JCEM 2001)
• Resistance exercise: Three to four sessions per week at 70-85% one-rep max raises LH pulse amplitude in men with functional hypogonadism.
• Body weight reduction: As noted, 10% weight loss in obese men raises testosterone measurably.

When Symptoms Warrant Resuming Therapy

If total testosterone remains below 300 ng/dL on two morning measurements at least 6 weeks apart, and the patient reports moderate to severe symptoms (validated by the AMS or ADAM questionnaire), resuming therapy is clinically justified. The Endocrine Society threshold for treatment initiation is a consistently low testosterone plus symptoms, the same threshold applies to resumption. (Bhasin S et al., JCEM 2018)

Lab Values That Confirm Safe Stopping

A patient can be considered to have successfully discontinued treatment when all three of the following are true on two consecutive measurements 4-6 weeks apart:

• Total testosterone above 400 ng/dL (some guidelines use 350 ng/dL as the minimum acceptable)
• LH above 2.0 mIU/mL, confirming axis is driving production
• Absence of moderate or severe hypogonadal symptoms on standardized questionnaire

If only testosterone is in range but LH is suppressed (below 1.5 mIU/mL), the axis has not recovered and the patient is still dependent on exogenous stimulation or the result is falsely reassuring. Dwyer AA et al. (JCEM 2016) showed that LH pulse frequency, not just basal LH, is the more sensitive marker of HPG axis recovery in CHH patients.